Safety and Use of Eptacog Beta 225 µg/kg in Patients With Haemophilia A or B With Inhibitors
Haemophilia · 2025
DOI: 10.1111/hae.70083 ↗Kurz gefasst
Klinische Studie (Phase I) in der Zeitschrift Haemophilia, 2025. Verfasst von Manuel Carcao und 7 weiteren Autor:innen. Beteiligte Einrichtung: The Hospital for Sick Children, Toronto, Canada. Hauptthemen laut MEDLINE: Factor VIIa, Hemophilia A, Hemophilia B. Die Arbeit nennt 39 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: LFB.
Abstract (Originalsprache)
Introduction
Eptacog beta is an activated recombinant human factor VII bypassing agent approved for treating bleeding episodes (BEs) in patients aged ≥12 years with haemophilia A or B with inhibitors. Two initial dose regimens (IDRs) of either 75 or 225 µg/kg, followed by 75 µg/kg, are approved. We examined the safety of eptacog beta 225 µg/kg across completed clinical trials.
Methods
This analysis included data from a Phase 1b trial of single doses of eptacog beta 25, 75 and 225 µg/kg in non‐bleeding adults with haemophilia and pooled data from two Phase 3 trials of the 75 and 225 µg/kg IDRs for treating BEs in adolescents and adults (PERSEPT 1) and children (PERSEPT 2).
Results
In the Phase 1b trial, 10 patients received a single eptacog beta infusion at each dose level. In the Phase 3 trials, 48 patients received the 75 µg/kg IDR (median 20.5 infusions/patient, range 1–137 infusions) and 50 patients received the 225 µg/kg IDR (median 14.5 infusions/patient, range 1–117 infusions). There was a similar incidence of treatment‐emergent adverse events (TEAEs) across all doses (225, 75 and 25 µg/kg) in the Phase 1b trial (0.8 vs. 1.0 vs. 2.1 events per infusion, respectively) and with the 225 versus 75 µg/kg IDR in the Phase 3 studies (0.046 vs. 0.029 events per infusion, respectively). No treatment‐related serious TEAEs, thromboembolic events, hypersensitivity reactions, deaths attributed to eptacog beta or neutralising antibodies were detected.
Conclusions
These findings demonstrate favourable safety and tolerability regarding the use of the 225 µg/kg IDR. Trial Registration ClinicalTrials.gov identifier: NCT01708564, NCT02020369, NCT02448680
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- The Hospital for Sick Children, Toronto, Canada.
- Catholic University of Louvain, Hemophilia Center of the Saint-Luc University Hospital, Brussels, Belgium.
- UC Davis Medical Center, Sacramento, California, USA.
- Lombardi Comprehensive Cancer Center, Georgetown University Medical Center, Washington, USA.
- Goethe University Hospital, Frankfurt, Germany.
- Orthopaedic Hemophilia Treatment Center, Los Angeles, USA.
ORCID-Profile: Manuel Carcao, Cédric Hermans, Craig Kessler, Wolfgang Miesbach, Doris Quon, Jerzy Windyga, Johnny Mahlangu
Förderung
- LFB
Zitieren
APA
Carcao, M., Hermans, C., Giermasz, A., Kessler, C., Miesbach, W., Quon, D., Windyga, J., & Mahlangu, J. (2025). Safety and Use of Eptacog Beta 225 µg/kg in Patients With Haemophilia A or B With Inhibitors. Haemophilia. https://doi.org/10.1111/hae.70083
Vancouver
Carcao M, Hermans C, Giermasz A, Kessler C, Miesbach W, Quon D, et al. Safety and Use of Eptacog Beta 225 µg/kg in Patients With Haemophilia A or B With Inhibitors. Haemophilia. 2025. doi:10.1111/hae.70083
BibTeX
@article{Carcao2025,
author = {Carcao, Manuel and Hermans, Cédric and Giermasz, Adam and Kessler, Craig and Miesbach, Wolfgang and Quon, Doris and Windyga, Jerzy and Mahlangu, Johnny},
title = {Safety and Use of Eptacog Beta 225 µg/kg in Patients With Haemophilia A or B With Inhibitors},
journal = {Haemophilia},
year = {2025},
doi = {10.1111/hae.70083}
}
EUVIMED